Torrelo A, Harto A, Sendagorta E, Czarnetzki B M, Ledo A
Department of Dermatology, Hospital Ramón y Cajal, Madrid, Spain.
Acta Derm Venereol. 1992 Sep;72(5):370-2.
Thirteen patients with a severe adult form of atopic dermatitis (AD) received 3.0 x 10(6) IU of recombinant interferon-alpha 2a (rIFN-alpha 2a) 3 times a week. A satisfactory response was obtained in 5 of them. Serum IgE levels in all 13 patients remained unchanged throughout the study. Flu-like symptoms were common, but clinical or laboratory adverse effects were otherwise slight. The moderately beneficial therapeutic effects observed in this study support a possible role for IFN-alpha in controlling immunologic deficiencies in atopic dermatitis.
13名患有严重成人型特应性皮炎（AD）的患者每周接受3次3.0×10⁶国际单位的重组干扰素-α 2a（rIFN-α 2a）治疗。其中5名患者获得了满意的反应。在整个研究过程中，所有13名患者的血清IgE水平均保持不变。流感样症状很常见，但其他方面的临床或实验室不良反应轻微。本研究中观察到的适度有益治疗效果支持了干扰素-α在控制特应性皮炎免疫缺陷方面可能发挥的作用。
